Saioa Garcia-Longarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Saioa Garcia-Longarte has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Arkaitz Carracedo
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA) Derio Spain
15 shared publications - Isabel Mendizabal
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA) Derio Spain
11 shared publications Onintza Carlevaris
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia, Spain
10 shared publicationsIanire Astobiza
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain
8 shared publications- Amaia Ercilla
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain
6 shared publications - Ianire Astobiza
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA) Derio Spain
6 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in Cell Death Discovery
A syngeneic mouse model of metastatic hormone-naive prostate cancer provides a platform for studying combination immunotherapy
Metastatic hormone-naive prostate cancer (mHNPC) refers to a small subset of diagnosed prostate tumors and presents very high mortality and poor response to available therapies. Despite its clinical relevance, we lack immunocompetent models that are both androgen-dependent and reliably metastatic, limiting the implementation of translational research strategies. Here we develop and characterize PL051, a syngeneic, bioluminescence tractable prostate carcinoma cell line derived from a Pten / Lkb1 double knockout genetic mouse model that reproducibly engrafts orthotopically in C57BL/6 mice, maintains androgen-receptor (AR) signaling, and consistently disseminates to soft tissues and bone. PL051 preserves Pten / Lkb1 loss and PI3K–AKT activation, shows intact AR responsiveness in vitro, and responds to AR-pathway intensification in vivo. We provide two complementary proof-of-concept evidence for the preclinical potential of this model. On one hand, we show the therapeutic benefit of combining androgen signaling inhibition and anti-PD1 treatment. On the other hand, we provide evidence showing that co-targeting myeloid cells with a CSF1R inhibitor further enhances therapeutic activity of checkpoint blockade by depleting suppressive macrophages and boosting T-cell recruitment. Together, this preclinical model fills a critical gap for studying mHNPC biology and provides a scalable, immune-competent model for testing rational combinatorial treatments.
- 31 October 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessA syngeneic mouse model of metastatic hormone-naive prostate cancer provides a platform for studying combination immunotherapy
Metastatic hormone-naive prostate cancer (mHNPC) refers to a small subset of diagnosed prostate tumors and presents very high mortality and poor response to available therapies. Despite its clinical relevance, we lack immunocompetent models that are both androgen-dependent and reliably metastatic, limiting the implementation of translational research strategies. Here we develop and characterize PL051, a syngeneic, bioluminescence tractable prostate carcinoma cell line derived from a Pten / Lkb1 double knockout genetic mouse model that reproducibly engrafts orthotopically in C57BL/6 mice, maintains androgen-receptor (AR) signaling, and consistently disseminates to soft tissues and bone. PL051 preserves Pten / Lkb1 loss and PI3K–AKT activation, shows intact AR responsiveness in vitro, and responds to AR-pathway intensification in vivo. We provide two complementary proof-of-concept evidence for the preclinical potential of this model. On one hand, we show the therapeutic benefit of combining androgen signaling inhibition and anti-PD1 treatment. On the other hand, we provide evidence showing that co-targeting myeloid cells with a CSF1R inhibitor further enhances therapeutic activity of checkpoint blockade by depleting suppressive macrophages and boosting T-cell recruitment. Together, this preclinical model fills a critical gap for studying mHNPC biology and provides a scalable, immune-competent model for testing rational combinatorial treatments.
- Open Access
A pan-cancer single-cell atlas of pericytes
Pericytes display marked tissue-specific transcriptional identities, raising the question of whether tumour-associated pericytes converge towards shared adaptive states across cancers. Here, we built a pan-cancer single-cell RNA sequencing atlas of pericytes, integrating nearly four million cells across nine tissues, complemented by spatial transcriptomic analyses. Despite their physiological diversity, pericytes were recurrently expanded in tumours and converged on a common transcriptional program, the tumour-associated pericyte signature (TAPS). TAPS robustly identified pericytes across datasets, outperforming canonical markers in tumour contexts. Tumour-associated pericytes further diversified into specialised states including extracellular matrix (ECM)-associated and interferon (IFN)-responsive programs, which occupy mutually exclusive tumour ecosystems. ECM-associated pericytes were enriched in desmoplastic, fibroblast-rich regions and were associated with adverse clinical outcomes across multiple cancer types. IFN-responsive pericytes accumulated in inflammatory niches, with macrophages implicated as candidate drivers of specialisation. Together, our multi-layered analysis defines convergent and specialised tumour-associated pericyte programs across human cancers.
Open AccessA pan-cancer single-cell atlas of pericytes
Pericytes display marked tissue-specific transcriptional identities, raising the question of whether tumour-associated pericytes converge towards shared adaptive states across cancers. Here, we built a pan-cancer single-cell RNA sequencing atlas of pericytes, integrating nearly four million cells across nine tissues, complemented by spatial transcriptomic analyses. Despite their physiological diversity, pericytes were recurrently expanded in tumours and converged on a common transcriptional program, the tumour-associated pericyte signature (TAPS). TAPS robustly identified pericytes across datasets, outperforming canonical markers in tumour contexts. Tumour-associated pericytes further diversified into specialised states including extracellular matrix (ECM)-associated and interferon (IFN)-responsive programs, which occupy mutually exclusive tumour ecosystems. ECM-associated pericytes were enriched in desmoplastic, fibroblast-rich regions and were associated with adverse clinical outcomes across multiple cancer types. IFN-responsive pericytes accumulated in inflammatory niches, with macrophages implicated as candidate drivers of specialisation. Together, our multi-layered analysis defines convergent and specialised tumour-associated pericyte programs across human cancers.
- Open Access
- 16 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17
Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression
Metabolic reprogramming is a hallmark of cancer, and the field has predominantly focused on investigating metabolic alterations in tumour cells. However, the relevance, mechanism and consequences of metabolic adaptations in stromal cells remain understudied. Here, we identify aspartoacylase (ASPA) as a metabolic enzyme consistently repressed in tumour stroma and cancer-associated fibroblasts (CAFs). Importantly, we report a reciprocal crosstalk between ASPA and Transforming Growth Factor Beta (TGFβ) signalling that influences fibroblast behaviour. TGFβ suppresses ASPA expression in fibroblasts, whereas ASPA restrains TGFβ-dependent myofibroblast conversion, extracelullar cell matrix (ECM) remodelling, angiogenesis and pro-tumoral macrophage phenotypes. Analyses of human specimens revealed a strong negative prognostic value for ASPA in different tumour types, associated with TGFβ signalling levels and the generation of aggressive pro-tumoral responses. Our findings unveil ASPA expression in fibroblasts as a gatekeeper of TGFβ responses and activation in cancer progression.
- 16 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17
Open AccessFibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression
Metabolic reprogramming is a hallmark of cancer, and the field has predominantly focused on investigating metabolic alterations in tumour cells. However, the relevance, mechanism and consequences of metabolic adaptations in stromal cells remain understudied. Here, we identify aspartoacylase (ASPA) as a metabolic enzyme consistently repressed in tumour stroma and cancer-associated fibroblasts (CAFs). Importantly, we report a reciprocal crosstalk between ASPA and Transforming Growth Factor Beta (TGFβ) signalling that influences fibroblast behaviour. TGFβ suppresses ASPA expression in fibroblasts, whereas ASPA restrains TGFβ-dependent myofibroblast conversion, extracelullar cell matrix (ECM) remodelling, angiogenesis and pro-tumoral macrophage phenotypes. Analyses of human specimens revealed a strong negative prognostic value for ASPA in different tumour types, associated with TGFβ signalling levels and the generation of aggressive pro-tumoral responses. Our findings unveil ASPA expression in fibroblasts as a gatekeeper of TGFβ responses and activation in cancer progression.
- Open Access
- 13 May 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (11) , 2918-2935
USP29 ‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer
Oxygen availability is frequently compromised in solid tumours, making intratumoural hypoxia a common feature of cancer. In prostate cancer (PCa), hypoxia is strongly associated with aggressive disease and poor prognosis. Hypoxia‐inducible factor (HIF) is the master transcriptional regulator mediating hypoxia adaptation and is mainly controlled through proteasomal degradation of its α‐subunit by the ubiquitin–proteasome system (UPS). However, the contribution of deubiquitinases (DUBs) to HIF signalling in PCa remains largely unexplored. Using a computational strategy based on CA9 expression as a surrogate of HIF activity, we identified Ubiquitin‐Specific Protease 29 (USP29) as a key regulator associated with hypoxia and tumour progression and severity in PCa. Mechanistically, USP29 functions as a noncanonical positive regulator of HIF‐α stability in a catalytic‐dependent manner. USP29 interacts with HIF‐1α, reduces its poly‐ubiquitination and protects it from proteasomal degradation across multiple cancer cell lines. Additionally, USP29 stabilizes HIF‐2α acting on the C‐terminal region of HIF‐α. These findings uncover a novel regulatory layer of HIF signalling and highlight USP29 as a potential therapeutic target in hypoxia‐driven PCa progression.
- 13 May 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (11) , 2918-2935
Open AccessUSP29 ‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer
Oxygen availability is frequently compromised in solid tumours, making intratumoural hypoxia a common feature of cancer. In prostate cancer (PCa), hypoxia is strongly associated with aggressive disease and poor prognosis. Hypoxia‐inducible factor (HIF) is the master transcriptional regulator mediating hypoxia adaptation and is mainly controlled through proteasomal degradation of its α‐subunit by the ubiquitin–proteasome system (UPS). However, the contribution of deubiquitinases (DUBs) to HIF signalling in PCa remains largely unexplored. Using a computational strategy based on CA9 expression as a surrogate of HIF activity, we identified Ubiquitin‐Specific Protease 29 (USP29) as a key regulator associated with hypoxia and tumour progression and severity in PCa. Mechanistically, USP29 functions as a noncanonical positive regulator of HIF‐α stability in a catalytic‐dependent manner. USP29 interacts with HIF‐1α, reduces its poly‐ubiquitination and protects it from proteasomal degradation across multiple cancer cell lines. Additionally, USP29 stabilizes HIF‐2α acting on the C‐terminal region of HIF‐α. These findings uncover a novel regulatory layer of HIF signalling and highlight USP29 as a potential therapeutic target in hypoxia‐driven PCa progression.
- Open Access
- 21 January 2026
- Published by Springer Nature in Nature
- Vol. 650 (8100) , E4
Publisher Correction: Polyamine-dependent metabolic shielding regulates alternative splicing
- 21 January 2026
- Published by Springer Nature in Nature
- Vol. 650 (8100) , E4
Open AccessPublisher Correction: Polyamine-dependent metabolic shielding regulates alternative splicing
- Top Cited PapersOpen Access
- 14 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8106) , 819-828
Polyamine-dependent metabolic shielding regulates alternative splicing
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1,2,3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding.
- 14 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8106) , 819-828
Top Cited PapersOpen AccessPolyamine-dependent metabolic shielding regulates alternative splicing
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1,2,3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding.
- Open Access
- 17 November 2025
- Published by Wiley in Molecular Oncology
- Vol. 20 (6) , 1429-1452
Transcriptional network analysis of PTEN ‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication
Among the extensive genomic alterations in prostate cancer, phosphatase and tensin homolog ( PTEN ) deletion stands out as one of the most consistently observed events. PTEN loss in prostate tumors is primarily associated with cancer‐cell proliferation and survival through the activation of the phosphoinositide 3‐kinase (PI3K)—protein kinase B (AKT)—mechanistic target of rapamycin (mTOR) (PI3K–AKT–mTOR) signaling pathway. However, the use of PTEN as a robust biomarker in clinical practice is hampered by its complex epigenetic, transcriptional and post‐translational regulation. In situ protein assessment by immunohistochemistry (IHC) captures PTEN protein status, but it does not report on associated tumor microenvironment remodeling. Here, we undertook an approach that combined PTEN immunoreactivity analysis with high‐throughput transcriptional analysis to gain insights into the downstream functional effects of PTEN protein loss in primary tumors. Our extensive bioinformatic analyses highlighted stromal remodeling as a prominent cancer cell‐extrinsic process associated with PTEN loss. By extending our transcriptomic computational strategy to Pten loss‐driven murine prostate cancer, we validated the causal role of Pten in the stromal reaction observed in clinical specimens. Mechanistically, we provide experimental evidence for the activation of a paracrine program that encompasses enhanced transforming growth factor beta (TGF‐β) signaling and that is compatible with the secretome of PTEN ‐deficient senescent cancer cells. Finally, our findings enable the sub‐stratification of tumors with PTEN loss based on their senescence‐associated stroma remodeling program to distinguish indolent from aggressive cases. Our study provides relevant biological context to the cellular and molecular alterations unleashed upon PTEN protein loss in prostate cancer.
- 17 November 2025
- Published by Wiley in Molecular Oncology
- Vol. 20 (6) , 1429-1452
Open AccessTranscriptional network analysis of PTEN ‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication
Among the extensive genomic alterations in prostate cancer, phosphatase and tensin homolog ( PTEN ) deletion stands out as one of the most consistently observed events. PTEN loss in prostate tumors is primarily associated with cancer‐cell proliferation and survival through the activation of the phosphoinositide 3‐kinase (PI3K)—protein kinase B (AKT)—mechanistic target of rapamycin (mTOR) (PI3K–AKT–mTOR) signaling pathway. However, the use of PTEN as a robust biomarker in clinical practice is hampered by its complex epigenetic, transcriptional and post‐translational regulation. In situ protein assessment by immunohistochemistry (IHC) captures PTEN protein status, but it does not report on associated tumor microenvironment remodeling. Here, we undertook an approach that combined PTEN immunoreactivity analysis with high‐throughput transcriptional analysis to gain insights into the downstream functional effects of PTEN protein loss in primary tumors. Our extensive bioinformatic analyses highlighted stromal remodeling as a prominent cancer cell‐extrinsic process associated with PTEN loss. By extending our transcriptomic computational strategy to Pten loss‐driven murine prostate cancer, we validated the causal role of Pten in the stromal reaction observed in clinical specimens. Mechanistically, we provide experimental evidence for the activation of a paracrine program that encompasses enhanced transforming growth factor beta (TGF‐β) signaling and that is compatible with the secretome of PTEN ‐deficient senescent cancer cells. Finally, our findings enable the sub‐stratification of tumors with PTEN loss based on their senescence‐associated stroma remodeling program to distinguish indolent from aggressive cases. Our study provides relevant biological context to the cellular and molecular alterations unleashed upon PTEN protein loss in prostate cancer.
- Open Access
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential
Background and objective: Cholangiocarcinoma (CCA) is a heterogeneous neoplasm of the biliary epithelium that easily infiltrates, metastasises and recurs. Magnesium disbalance is a hallmark of CCA, with the magnesium transporter cyclin M4 (CNNM4) being a key driver of various hepatic diseases. This study aims to unravel the role of CNNM4 in the initiation and progression of CCA. Design: CNNM4 protein and gene expression were assessed in vitro, in vivo and in patients with CCA. Silencing of CNNM4 was effectively achieved by using small interfering RNA (siRNA) or short hairpin RNA in CCA cell lines and GalNAc-conjugated siRNA in a transposon-based CCA mice model. The impact of CNNM4 on tumour cell proliferation, migration and invasion to the lungs was evaluated using the chicken chorioallantoic membrane model. Proteomic analysis was employed to elucidate the underlying molecular mechanisms. Results: CNNM4 was upregulated in CCA samples from humans, mice and cell lines. Functional studies demonstrated that CNNM4 deficiency attenuates cell growth, chemoresistance, migration, invasion, cancer stem cell properties and Warburg effect in vitro and in vivo. Proteomic analysis identified nuclear protein 1 as an upstream regulator of CNNM4-induced ferroptosis in CCA, ultimately leading to cell death. The iron chelator deferiprone could reverse the decreased proliferation induced by CNNM4 silencing, while inhibition of the heme oxygenase-1 by zinc protoporphyrin IX affected only the growth of cells with no targeted CNNM4 inhibition, highlighting the specificity of ferroptosis in CNNM4-associated effects. Conclusion: This study reveals that increased CNNM4 expression drives CCA progression and malignancy and that its inhibition may be an effective therapeutic strategy to limit proliferation and metastasis in patients with CCA.
Open AccessRole of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential
Background and objective: Cholangiocarcinoma (CCA) is a heterogeneous neoplasm of the biliary epithelium that easily infiltrates, metastasises and recurs. Magnesium disbalance is a hallmark of CCA, with the magnesium transporter cyclin M4 (CNNM4) being a key driver of various hepatic diseases. This study aims to unravel the role of CNNM4 in the initiation and progression of CCA. Design: CNNM4 protein and gene expression were assessed in vitro, in vivo and in patients with CCA. Silencing of CNNM4 was effectively achieved by using small interfering RNA (siRNA) or short hairpin RNA in CCA cell lines and GalNAc-conjugated siRNA in a transposon-based CCA mice model. The impact of CNNM4 on tumour cell proliferation, migration and invasion to the lungs was evaluated using the chicken chorioallantoic membrane model. Proteomic analysis was employed to elucidate the underlying molecular mechanisms. Results: CNNM4 was upregulated in CCA samples from humans, mice and cell lines. Functional studies demonstrated that CNNM4 deficiency attenuates cell growth, chemoresistance, migration, invasion, cancer stem cell properties and Warburg effect in vitro and in vivo. Proteomic analysis identified nuclear protein 1 as an upstream regulator of CNNM4-induced ferroptosis in CCA, ultimately leading to cell death. The iron chelator deferiprone could reverse the decreased proliferation induced by CNNM4 silencing, while inhibition of the heme oxygenase-1 by zinc protoporphyrin IX affected only the growth of cells with no targeted CNNM4 inhibition, highlighting the specificity of ferroptosis in CNNM4-associated effects. Conclusion: This study reveals that increased CNNM4 expression drives CCA progression and malignancy and that its inhibition may be an effective therapeutic strategy to limit proliferation and metastasis in patients with CCA.
- Open Access
- 22 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1
Correction: The PP2A regulator IER5L supports prostate cancer progression
- 22 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1
Open AccessCorrection: The PP2A regulator IER5L supports prostate cancer progression
- Open Access
Loss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards hexosamine biosynthesis
The acquisition of metastatic features in tumor cells encompasses genetic and non-genetic adaptation, including reprogramming of cellular metabolism. Here we show that loss of UFMylation reroutes glucose metabolism, promotes invasive capacity and supports prostate cancer metastasis. Through transcriptome-based bioinformatics analysis, we identified a reduction in the ubiquitin-like modifier UFM1 and its ligase UFL1 in metastatic prostate cancer. We demonstrate that loss of UFMylation results in enhanced cancer cell dissemination and a switch from cellular proliferation to invasion. Using biotin-based proteomics, we identified phosphofructokinase (PFKAP) as an unprecedented UFMylation substrate. Consistent with UFMylation playing a role in the regulation of phosphofructokinase activity, loss of UFMylation reduced glucose metabolism in favour of hexosamine biosynthesis, which resulted in elevated glycosylation of proteins relevant for cell invasion. These results reveal a role for UFMylation in the regulation of phosphofructokinase and glucose metabolism to support prostate cancer metastasis.
Open AccessLoss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards hexosamine biosynthesis
The acquisition of metastatic features in tumor cells encompasses genetic and non-genetic adaptation, including reprogramming of cellular metabolism. Here we show that loss of UFMylation reroutes glucose metabolism, promotes invasive capacity and supports prostate cancer metastasis. Through transcriptome-based bioinformatics analysis, we identified a reduction in the ubiquitin-like modifier UFM1 and its ligase UFL1 in metastatic prostate cancer. We demonstrate that loss of UFMylation results in enhanced cancer cell dissemination and a switch from cellular proliferation to invasion. Using biotin-based proteomics, we identified phosphofructokinase (PFKAP) as an unprecedented UFMylation substrate. Consistent with UFMylation playing a role in the regulation of phosphofructokinase activity, loss of UFMylation reduced glucose metabolism in favour of hexosamine biosynthesis, which resulted in elevated glycosylation of proteins relevant for cell invasion. These results reveal a role for UFMylation in the regulation of phosphofructokinase and glucose metabolism to support prostate cancer metastasis.